- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:52 | Immunovia AB: Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer | 48 | PR Newswire | LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the... ► Artikel lesen | |
| 28.11. | IMMUNOVIA AB: Immunovia to present at the Redeye Technology & Life Science Day | 2 | Cision News | ||
| 27.11. | Immunovia AB: Immunovia Publishes Interim Report for January-September 2024 | 202 | PR Newswire | LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 15.11. | IMMUNOVIA AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers | 3 | Cision News | ||
| 12.11. | Immunovia AB: Invitation to Immunovia's Q3 presentation | 124 | PR Newswire | LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen | |
| 07.11. | Immunovia AB: Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium | 249 | PR Newswire | SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual... ► Artikel lesen | |
| 07.10. | Immunovia AB: Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer | 330 | PR Newswire | LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples... ► Artikel lesen | |
| 02.10. | Immunovia AB: Immunovia completes analytical validation of its next-generation pancreatic cancer test | 278 | PR Newswire | LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation... ► Artikel lesen | |
| 30.09. | Change in number of shares and votes in Immunovia AB (publ) | 209 | PR Newswire | LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of... ► Artikel lesen | |
| 27.09. | Nasdaq Stockholm AB: New equity right for trading, Immunovia AB (publ) | 248 | GlobeNewswire | At the request of Immunovia AB (publ), Immunovia AB equity rights TO 2 and TO 3
will be traded on Nasdaq Stockholm as from September 30, 2024.
IMMNOV TO 2
Security name: Immunovia AB TO 2
---------------------------------
Short... ► Artikel lesen | |
| 16.09. | Immunovia AB: Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference | 378 | PR Newswire | LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the... ► Artikel lesen | |
| 12.09. | IMMUNOVIA AB: Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue | 2 | Cision News | ||
| 03.09. | IMMUNOVIA AB: Immunovia announces final outcome in rights issue | 2 | Cision News | ||
| 02.09. | IMMUNOVIA AB: Immunovia publishes preliminary outcome in rights issue | 1 | Cision News | ||
| 13.08. | Nasdaq Stockholm AB: Listing of units rights and paid subscription units of Immunovia AB | 359 | GlobeNewswire | With effect from August 16, 2024, the unit rights of Immunovia AB will be
traded on the list for Equity rights. Trading will continue up until and
including August 27, 2024.
Instrument: Unit rights... ► Artikel lesen | |
| 12.08. | IMMUNOVIA AB: Immunovia publishes prospectus in connection with forthcoming rights issue | 1 | Cision News | ||
| 12.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.08.2024 | 421 | Xetra Newsboard | Das Instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024 The instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY is traded... ► Artikel lesen | |
| 06.08. | IMMUNOVIA AB: Immunovia announces final terms of rights issue | 4 | Cision News | ||
| 05.08. | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 895 | PR Newswire | LUND, Sweden, Aug. 5, 2024 /PRNewswire/ --
April-June 2024
Net sales, consisting of royalties, amounted to 85 KSEK (412)Net earnings amounted to -25.6 MSEK (-185.1), where one-off... ► Artikel lesen | |
| 05.08. | Immunovia AB: Immunovia's next-generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health | 115 | PR Newswire | LUND, Sweden, Aug. 5, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces that the company's next-generation test to detect pancreatic... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 10,296 | -1,17 % | Out-of-consensus buy ideas according to Goldman: CAG, TRIP, TDOC | ||
| BECTON DICKINSON | 212,10 | +1,87 % | Dividendenbekanntmachungen (09.12.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALMACENES EXITO SA ADR US02028M1053 0,0353 USD 0,0334 EUR ALPHABET INC CDR CA02080K1049 0,0331 CAD 0,0221 EUR ALPHABET INC CL A US02079K3059 0... ► Artikel lesen | |
| HIMS & HERS HEALTH | 31,960 | -1,36 % | Compounded weight-loss drugs a high-growth revenue stream for Hims & Hers, brokerage says | ||
| DEXCOM | 74,13 | +0,71 % | Das Wertpapier von Dexcom heute schwach: Kurs rutscht deutlich ab! (74,0131 €) | Die Aktie von Dexcom zählt am Donnerstag zu den großen Verlierern an der Börse. Der Titel verbilligt sich heute deutlich. Ein Verlust von 3,49 Prozent zeigt die Kurstafel für der Anteilsschein von Dexcom... ► Artikel lesen | |
| INVITAE | 0,110 | 0,00 % | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,200 | +3,45 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices | BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| RYMAN HEALTHCARE | 2,370 | -1,99 % | RYMAN HEALTHCARE LIMITED: SPH Notice - Cooper Investors Pty Limited | ||
| CYTOSORBENTS | 0,835 | -1,18 % | CytoSorbents sets terms for anticipated Rights Offering | ||
| TEMPEST THERAPEUTICS | 0,870 | +0,93 % | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| ONTRAK | 1,555 | -17,40 % | OTRK-Aktie stürzt auf 52-Wochen-Tief von 1,69 US-Dollar | ||
| PATTERSON COMPANIES | 21,600 | 0,00 % | Patterson Companies Inc. Q2 Profit Decreases, Misses Estimates | SAINT PAUL (dpa-AFX) - Patterson Companies Inc. (PDCO) revealed earnings for second quarter that decreased from last year and missed the Street estimates.The company's earnings came in at $26.77... ► Artikel lesen | |
| STAAR SURGICAL | 24,110 | +0,67 % | STAAR Surgical stock hits 52-week low at $25.87 | ||
| SENSEONICS | 0,264 | +9,65 % | Senseonics-Aktie erreicht 52-Wochen-Tief bei 0,28 US-Dollar |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+1,81 %) liegt der Kurs bei 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
